Alibaba Health Information Technology Limited Fundamental Analysis
Alibaba Health Information Technology Limited Fundamental Analysis
Alibaba Health Information Technology Limited (0241.HK) shows weak financial fundamentals with a PE ratio of 25.17, profit margin of 5.65%, and ROE of 10.95%. The company generates $34.2B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 56.6/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 0241.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak0241.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate0241.HK shows balanced valuation metrics.
Growth Score
Moderate0241.HK shows steady but slowing expansion.
Financial Health Score
Excellent0241.HK maintains a strong and stable balance sheet.
Profitability Score
Weak0241.HK struggles to sustain strong margins.
Key Financial Metrics
Is 0241.HK Expensive or Cheap?
P/E Ratio
0241.HK trades at 25.17 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 0241.HK's PEG of 0.29 indicates potential undervaluation.
Price to Book
The market values Alibaba Health Information Technology Limited at 2.74 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 37.64 times EBITDA. This signals the market has high growth expectations.
How Well Does 0241.HK Make Money?
Net Profit Margin
For every $100 in sales, Alibaba Health Information Technology Limited keeps $5.65 as profit after all expenses.
Operating Margin
Core operations generate 5.36 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $10.95 in profit for every $100 of shareholder equity.
ROA
Alibaba Health Information Technology Limited generates $8.41 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Alibaba Health Information Technology Limited generates limited operating cash flow of $1.44B, signaling weaker underlying cash strength.
Free Cash Flow
Alibaba Health Information Technology Limited produces free cash flow of $1.44B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.09 in free cash annually.
FCF Yield
0241.HK converts 2.96% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
25.17
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.29
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.74
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.42
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.003
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.03
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.11
vs 25 benchmark
ROA
Return on assets percentage
0.08
vs 25 benchmark
ROCE
Return on capital employed
0.10
vs 25 benchmark
How 0241.HK Stacks Against Its Sector Peers
| Metric | 0241.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 25.17 | 29.43 | Better (Cheaper) |
| ROE | 10.95% | 426.00% | Weak |
| Net Margin | 5.65% | -11473.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.79 | Strong (Low Leverage) |
| Current Ratio | 3.03 | 5.14 | Strong Liquidity |
| ROA | 8.41% | -17.00% (disorted) | Weak |
0241.HK outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Alibaba Health Information Technology Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation